Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10-K/A
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
News
TYPE
HEADLINE
FILED AT
8-K
RenovoRx Reports Record Q3 2026 Revenue Exceeding $1 Million and Provides Business Update
8-K
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
8-K/A
RenovoRx Reports Record Q2 2026 Results and Raises Full-Year Revenue Guidance
8-K
RenovoRx Reports Record Q2 2026 Results and Raises Full-Year Revenue Guidance
8-K
RenovoRx to Host JonesTrading Webinar on TAMP™ Platform and Pancreatic Cancer Landscape
8-K
RenovoRx, Inc. Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Prospectus
TYPE
HEADLINE
FILED AT
424B3
SHARE RESALE REGISTRATION | Shares: 10,638,790
424B5
November 2025 ATM | Amount sold to date: $0 | Float: 35,649,916
424B5
SHELF OFFERING | Shares amount: 11,523,810 | Share price: $1.05 | Offering amount: $12,100,001.00 | Float: 23,585,842 | Amount sold to date: $0.00 | Bank: Titan Partners Group a division of American Capital Partners
